文献速递脊柱关节炎

比美吉珠单抗治疗中轴型脊柱关节炎的性别差异:BE MOBILE 52周结果

Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

两项III期试验的事后分析评估比美吉珠单抗治疗中轴型脊柱关节炎的性别差异。16周时男性应答优于女性,52周时女性在复合及患者报告结局上持续改善,但男性数值应答仍更高;两性客观炎症均显著改善并维持至52周。

要点

  • 16周时男性比美吉珠单抗应答优于女性,52周时女性在多结局上持续改善。
  • 两性MRI与hs-CRP所反映的客观炎症在16周和52周均降至相似低水平。
  • r-axSpA男性占72.3%,nr-axSpA男性占54.3%,性别分布存在亚型差异。

核心结论

  • 男性中轴型脊柱关节炎患者对比美吉珠单抗的早期临床应答优于女性,但女性在52周时复合及患者报告结局上显示更长期的改善。
  • 尽管基线存在差异,两性在16周和52周时客观炎症(MRI、hs-CRP)均显著改善并维持于相似低水平。

研究设计与样本

  • BE MOBILE 1(NCT03928704)和BE MOBILE 2(NCT03928743)两项III期试验的事后分析,分别纳入nr-axSpA和r-axSpA患者。
  • 比较第16周(比美吉珠单抗 vs 安慰剂治疗效应)和第52周(仅比美吉珠单抗随机化患者)的性别差异,二分类结局用比值比、连续结局用差值、hs-CRP因偏态分布用基线比值。

主要发现

  • nr-axSpA性别分布均衡(男性54.3%),而r-axSpA男性占72.3%。
  • 第16周,比美吉珠单抗随机化男性在ASAS40、ASDAS<2.1及BASDAI、BASFI和HRQoL改善上通常较女性有更好的治疗应答(对比安慰剂)。
  • 第52周,女性在这些结局上显示更长期改善,但男性数值应答仍持续更高。
  • 第16周和第52周,两性活动性炎症(MRI、hs-CRP)均降至相似低水平,尽管基线存在差异。

关键数值与推荐

  • 疾病活动度指标包括ASAS40、ASDAS<2.1、BASDAI;功能指标BASFI;另评估疼痛、疲劳、HRQoL及客观炎症(MRI、hs-CRP)。

临床怎么用

  • 临床中应关注中轴型脊柱关节炎患者对比美吉珠单抗应答的性别差异:男性早期应答更优,女性长期复合及患者报告结局改善更持久。
  • 无论性别,客观炎症在16周和52周均显著改善,支持将MRI和hs-CRP作为监测炎症控制的指标。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess sex-based differences in response to bimekizumab in patients with axial spondyloarthritis (axSpA) from two phase 3 trials. METHODS: Improvements to week 52 in measures of disease activity (ASAS40, ASDAS <2.1, BASDAI) and function (BASFI), pain, fatigue, health-related quality of life (HRQoL) and objective signs of inflammation (MRI, hs-CRP) were assessed post hoc in patients with non-radiographic (nr-) and radiographic (r-)axSpA from BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743), respectively. Comparisons were made between sexes at week 16 (bimekizumab vs placebo treatment effect) and week 52 (treatment response in bimekizumab-randomized patients only) using odds ratios for dichotomous outcomes and difference values for continuous outcomes. For hs-CRP, ratio to baseline was calculated due to skewed distribution. RESULTS: While sex distribution was balanced in nr-axSpA (54.3% male), 72.3% of patients with r-axSpA were male. At week 16, bimekizumab-randomized male patients typically had better treatment responses vs placebo compared with female patients across ASAS40, ASDAS <2.1 and improvements in BASDAI, BASFI and measures of HRQoL. At week 52, female patients had longer-term improvements across these outcomes, though male patients continued to have numerically higher treatment responses. In contrast, active inflammation (MRI, hs-CRP) was reduced to similarly low levels in both sexes at week 16 and maintained to week 52, despite baseline differences. CONCLUSION: Although male patients had earlier clinical responses to bimekizumab treatment, female patients demonstrated longer-term improvements in composite and patient-reported outcomes. Both sexes had substantial improvements in objective inflammation at week 16 and 52, despite baseline differences. TRIAL REGISTRATION: Clinicaltrials.gov; NCT03928704 and NCT03928743.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rudwaleit M, Ramiro S, Poddubnyy D, et al. Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE trials. Rheumatology (Oxford). 2026. PMID: 42605056. doi:10.1093/rheumatology/keag425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。